NCT03502954View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039

PHASE1TerminatedINTERVENTIONAL

Enrollment

66

Participants

Timeline

Start Date

February 26, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

March 20, 2020

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

ABY-039

ABY-039

BIOLOGICAL

Placebo

Placebo

Trial Locations (1)

Unknown

PAREXEL Early Phase Unit, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

Affibody

INDUSTRY

NCT03502954 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039 | Biotech Hunter | Biotech Hunter